Registry for Migraine - Clinical Core

Summary

This study aims to investigate the effect of erenumab on efficacy outcomes, tolerability outcomes, and patient-reported outcomes in individuals with migraine. Furthermore, the study aims to identify clinical predictors of erenumab response.

Timeline

Start

2020-09-25

Primary completion

2022-10

Completion

2022-10

Publications

• Thuraiaiyah J, Christensen RH, Al-Khazali HM, Ashina M, Katsarava Z, Ashina H. MIDAS and HIT-6 Questionnaires Versus Headache Diaries for Monitoring Treatment Response to Erenumab in Migraine: A REFORM Study. Eur J Neurol. 2026 Apr;33(4):e70542. doi: 10.1111/ene.70542.
• Jakobsen JT, Karlsson WK, Christensen RH, Al-Khazali HM, Ashina M, Ashina H. Effects of erenumab on migraine aura frequency: a REFORM study. J Headache Pain. 2026 Mar 26;27(1):129. doi: 10.1186/s10194-026-02338-7.
• Thuraiaiyah J, Christensen RH, Al-Khazali HM, Wiggers A, Ashina M, Ashina H. Overlap between perceived triggers, premonitory symptoms and symptom persistence across migraine phases: A REFORM study. Cephalalgia. 2025 Aug;45(8):3331024251364234. doi: 10.1177/03331024251364234. Epub 2025 Aug 26.
• Karlsson WK, Christensen RH, Al-Khazali HM, Kallemose T, Jawad BN, Andersen O, Ashina M, Ashina H. Plasma SuPAR and therapeutic response to erenumab in migraine: a REFORM study. J Headache Pain. 2025 Apr 24;26(1):86. doi: 10.1186/s10194-025-02037-9.
• Karlsson WK, Ashina H, Cullum CK, Christensen RH, Al-Khazali HM, Amin FM, Ashina M; REFORM Investigators. The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics. J Headache Pain. 2023 Jun 12;24(1):70. doi: 10.1186/s10194-023-01604-2.

Drugs

Indications